Latest Content

Dr. Daniel Peters discussed targeted therapies and regimens that patients with acute myeloid leukemia, or AML, should be aware of.

The FDA approved Breyanzi for adults with relapsed or refractory marginal zone lymphoma who received at least two prior lines of systemic therapy.

I’ve lived with stage 4 breast cancer for 11 years, and each day brings gratitude for my family, my oncologist, and the care that keeps me going.

Stage 1 myelofibrosis is a manageable early-stage blood cancer that requires ongoing monitoring and personalized care to support long-term health.

As part of her journey with stage 3 inflammatory breast cancer, Lindsey Gunter experienced chemotherapy side effects so severe that she was unable to walk.

I experienced acute myeloid leukemia twice. Had it not been for follow up appointments I would not be here.

This guide explains how squamous cell lung cancer is diagnosed and treated at each stage to help patients talk openly with their oncology team.

The U.S. commercial launch of LYMPHIR offers a new treatment option for patients with relapsed/refractory stage 1 to 3 cutaneous T-cell lymphoma.

Dr. Girindra Raval sat down for an interview with CURE to discuss what patients with EGFR-mutated lung cancer should know about their treatment options.

Nona Baker, who was first diagnosed with a blood cancer in 1991, shares her experience with polycythemia vera.

In November 2025, the FDA issued multiple oncology approvals that expanded treatment access for patients with breast, lung, blood and solid tumor cancers.

The FDA granted traditional approval to Jaypirca for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

Dr. Charles M. Rudin discussed recent treatment advancements for patients with small cell lung cancer.